Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: IXICO plc

Capitalization 7.23M 9.73M 8.35M 7.55M 13.2M 893M 13.62M 88.91M 35.6M 428M 36.5M 35.73M 1.53B P/E ratio 2026 *
-4.33x
P/E ratio 2027 * -
Enterprise value 6.13M 8.25M 7.08M 6.4M 11.19M 757M 11.55M 75.38M 30.19M 363M 30.95M 30.29M 1.3B EV / Sales 2026 *
0.82x
EV / Sales 2027 * -
Free-Float
69.39%
Yield 2026 *
-
Yield 2027 * -
1 day-2.46%
1 week-3.08%
Current month-0.22%
1 month-25.78%
3 months-37.89%
6 months-36.60%
Current year-35.25%
1 week 7.6
Extreme 7.6
8
1 month 7
Extreme 7
10.85
Current year 7
Extreme 7
12
1 year 7
Extreme 7
15
3 years 6.35
Extreme 6.35
25
5 years 6.35
Extreme 6.35
115
10 years 6.35
Extreme 6.35
127
Manager TitleAgeSince
Chief Executive Officer 53 2024-08-18
Director of Finance/CFO 50 2019-08-20
Chief Tech/Sci/R&D Officer - 2020-12-31
Director TitleAgeSince
Chairman 50 -
Director/Board Member 50 2019-08-20
Director/Board Member 60 2022-01-20
Change 5d. change 1-year change 3-years change Capi.($)
-2.46%-3.08%-18.19%-68.63% 9.73M
-0.83%-6.47%-7.94%-6.54% 44.92B
+1.03%+2.81%+25.85%+41.23% 33.88B
+0.98%-8.44%+16.94%+45.41% 30.76B
-4.27%-1.74%-9.46%-13.35% 28.69B
-0.93%-1.62%+168.50%+376.20% 19.59B
+0.25%+0.54%+74.06%+126.46% 14.76B
-2.46%+0.30%+38.35%+166.08% 13.25B
-0.66%-5.42%+25.34%+0.22% 13.06B
-5.37%+2.17%+22,573.45%+3,414.48% 12.12B
Average -1.47%-0.04%+2,288.69%+408.16% 21.1B
Weighted average by Cap. -1.02%-0.24%+1,324.77%+260.32%

Financials

2026 *2027 *
Net sales 7.5M 10.09M 8.67M 7.83M 13.7M 927M 14.13M 92.26M 36.94M 444M 37.87M 37.07M 1.59B -
Net income -1.63M -2.19M -1.88M -1.7M -2.98M -201M -3.07M -20.05M -8.03M -96.58M -8.23M -8.06M -346M -
Net Debt -1.1M -1.48M -1.27M -1.15M -2.01M -136M -2.07M -13.53M -5.42M -65.17M -5.55M -5.44M -233M -
Logo IXICO plc
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
Employees
79
Date Price Change Volume
26-03-11 7.608 p -2.46% 101,000
26-03-10 7.800 p 0.00% 34,800
26-03-09 7.800 p 0.00% 244,117
26-03-06 7.800 p 0.00% 1,343
26-03-05 7.800 p -0.64% 9,428
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0780GBP
Average target price
0.2600GBP
Spread / Average Target
+233.33%

Annual profits - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW